The acne drugs market consists of sales of prescription acne drugs (Salicylic acid, Retin-A Micro, Onexton, and Solodyn) and related OTC non-prescription products (cleansers, lotions, gels, toners, masks and pads containing acne-fighting ingredients) which are used to treat skin diseases such as acne vulgaris and acne rosacea. Based on the type of acne, this market is segmented into inflammatory acne and Non-Inflammatory acne. Market in this report does not include the sales of drugs used for Dermatitis and Psoriasis.
The global acne drugs market is expected to decline from $4.6 billion in 2019 to $3.9 billion in 2020 at a compound annual growth rate (CAGR) of -15%. The decline is mainly because of drop in sales due to the lockdown measures to contain COVID-19 spread. Apart from restricting non-emergency medical services, new rules of the governments across the globe has forced many companies in the dermatology drug market to halt their business operations which has impacted the market growth. The market is then expected to recover and grow at a CAGR of 4.3% from 2021 and reach $5.7 billion in 2023.
